Literature DB >> 9159345

p16INK4 and p15INK4B alterations in primary gynecologic malignancy.

Y F Wong1, T K Chung, T H Cheung, T Nobori, S F Yim, K W Lai, M Phil, A L Yu, M B Diccianni, T Z Li, A M Chang.   

Abstract

Chromosome 9 abnormalities have been found in primary tumors and cell lines from human gynecologic malignancy. Alterations of p16INK4 and p15INK4B genes mapped on the band p21 of chromosome 9 have been detected in various human tumors, but the role of these genes as tumor suppressors in vivo appear to be dependent on tumor type. Polymerase chain reaction (PCR)-based analysis was performed to search for lesions of these genes in 202 primary gynecologic malignancies. Homozygous deletions of p16INK4 were detected in 7 of 128 (5%) cervical, 1 of 41 (2%) endometrial, 2 of 27 (7%) ovarian, and 3 of 6 (50%) vulvar carcinomas, while homozygous deletions of p15INK4B were detected in 19 of 128 (15%) cervical, 1 of 41 (2%) endometrial, 9 of 27 (33%) ovarian, and 3 of 6 (50%) vulvar carcinomas, respectively. No mutations were found in exon 2 of p16INK4 from 161 cases of gynecologic malignancy without deletion of p16INK4. All 3 cases of vulvar carcinoma showing homozygous deletions of p16INK4 and p15INK4B were at advanced clinical stage (stage III-IV), while all 7 cases of cervical carcinoma and 2 cases of ovarian carcinoma showing homozygous deletion of p16INK4 were at early stage (stage I-II). The results indicate that homozygous deletions of p16INK4 and/or p15INK4B genes may play a role in a subset of primary gynecologic malignancy.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9159345     DOI: 10.1006/gyno.1997.4669

Source DB:  PubMed          Journal:  Gynecol Oncol        ISSN: 0090-8258            Impact factor:   5.482


  8 in total

Review 1.  Role of p53 and Rb in ovarian cancer.

Authors:  David C Corney; Andrea Flesken-Nikitin; Jinhyang Choi; Alexander Yu Nikitin
Journal:  Adv Exp Med Biol       Date:  2008       Impact factor: 2.622

2.  The hypermethylation and protein expression of p16 INK4A and DNA repair gene O6-methylguanine-DNA methyltransferase in various uterine cervical lesions.

Authors:  Zhenhua Lin; Meihua Gao; Xianglan Zhang; Young-Sik Kim; Eung-Seok Lee; Han-Kyeom Kim; Insun Kim
Journal:  J Cancer Res Clin Oncol       Date:  2005-03-23       Impact factor: 4.553

3.  High-resolution genomic alterations in Barrett's metaplasia of patients who progress to esophageal dysplasia and adenocarcinoma.

Authors:  Jorge L Sepulveda; Elena V Komissarova; Sarawut Kongkarnka; Richard A Friedman; Jon M Davison; Brynn Levy; Diana Bryk; Vaidehi Jobanputra; Armando Del Portillo; Gary W Falk; Joshua R Sonett; Charles J Lightdale; Julian A Abrams; Timothy C Wang; Antonia R Sepulveda
Journal:  Int J Cancer       Date:  2019-05-02       Impact factor: 7.396

4.  p16INK4A alterations are accompanied by aberrant protein immunostaining in endometrial carcinomas.

Authors:  Andrzej Semczuk; Carsten Boltze; Barbara Marzec; Anna Szczygielska; Albert Roessner; Regine Schneider-Stock
Journal:  J Cancer Res Clin Oncol       Date:  2003-08-14       Impact factor: 4.553

Review 5.  Emerging therapeutic targets in endometrial cancer.

Authors:  Konstantin J Dedes; Daniel Wetterskog; Alan Ashworth; Stan B Kaye; Jorge S Reis-Filho
Journal:  Nat Rev Clin Oncol       Date:  2011-01-11       Impact factor: 66.675

6.  Alteration of p16 and p15 genes in human uterine tumours.

Authors:  R Nakashima; M Fujita; T Enomoto; T Haba; K Yoshino; H Wada; H Kurachi; M Sasaki; K Wakasa; M Inoue; G Buzard; Y Murata
Journal:  Br J Cancer       Date:  1999-05       Impact factor: 7.640

7.  Epstein-Barr virus and p16INK4A methylation in squamous cell carcinoma and precancerous lesions of the cervix uteri.

Authors:  Na Rae Kim; Zhenhua Lin; Kyong Rae Kim; Hyun Yee Cho; Insun Kim
Journal:  J Korean Med Sci       Date:  2005-08       Impact factor: 2.153

8.  Expression of p15INK⁴b and p57KIP² and relationship with clinicopathological features and prognosis in patients with vulvar squamous cell carcinoma.

Authors:  Ruth Holm; Mette Førsund; Mai T Nguyen; Jahn M Nesland; Claes G Trope
Journal:  PLoS One       Date:  2013-04-08       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.